AU2012272837B2 - Influenza virus mutants and uses therefor - Google Patents

Influenza virus mutants and uses therefor Download PDF

Info

Publication number
AU2012272837B2
AU2012272837B2 AU2012272837A AU2012272837A AU2012272837B2 AU 2012272837 B2 AU2012272837 B2 AU 2012272837B2 AU 2012272837 A AU2012272837 A AU 2012272837A AU 2012272837 A AU2012272837 A AU 2012272837A AU 2012272837 B2 AU2012272837 B2 AU 2012272837B2
Authority
AU
Australia
Prior art keywords
virus
influenza
δτμ
μ2κο
ferrets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012272837A
Other languages
English (en)
Other versions
AU2012272837A1 (en
AU2012272837A2 (en
Inventor
Pamuk Bilsel
Yasuko Hatta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FluGen Inc
Original Assignee
FluGen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FluGen Inc filed Critical FluGen Inc
Publication of AU2012272837A1 publication Critical patent/AU2012272837A1/en
Publication of AU2012272837A2 publication Critical patent/AU2012272837A2/en
Application granted granted Critical
Publication of AU2012272837B2 publication Critical patent/AU2012272837B2/en
Priority to AU2018200490A priority Critical patent/AU2018200490B2/en
Priority to AU2018200488A priority patent/AU2018200488B2/en
Priority to AU2020201760A priority patent/AU2020201760B2/en
Priority to AU2023204165A priority patent/AU2023204165A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2012272837A 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor Active AU2012272837B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2018200490A AU2018200490B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2018200488A AU2018200488B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2020201760A AU2020201760B2 (en) 2011-06-24 2020-03-10 Influenza virus mutants and uses therefor
AU2023204165A AU2023204165A1 (en) 2011-06-24 2023-06-29 Influenza virus mutants and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501034P 2011-06-24 2011-06-24
US61/501,034 2011-06-24
PCT/US2012/043606 WO2012177924A2 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2018200490A Division AU2018200490B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2018200488A Division AU2018200488B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor

Publications (3)

Publication Number Publication Date
AU2012272837A1 AU2012272837A1 (en) 2014-01-16
AU2012272837A2 AU2012272837A2 (en) 2014-01-30
AU2012272837B2 true AU2012272837B2 (en) 2017-11-02

Family

ID=47423213

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012272837A Active AU2012272837B2 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
AU2018200488A Active AU2018200488B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2018200490A Active AU2018200490B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2020201760A Active AU2020201760B2 (en) 2011-06-24 2020-03-10 Influenza virus mutants and uses therefor
AU2023204165A Pending AU2023204165A1 (en) 2011-06-24 2023-06-29 Influenza virus mutants and uses therefor

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018200488A Active AU2018200488B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2018200490A Active AU2018200490B2 (en) 2011-06-24 2018-01-22 Influenza virus mutants and uses therefor
AU2020201760A Active AU2020201760B2 (en) 2011-06-24 2020-03-10 Influenza virus mutants and uses therefor
AU2023204165A Pending AU2023204165A1 (en) 2011-06-24 2023-06-29 Influenza virus mutants and uses therefor

Country Status (11)

Country Link
US (7) US9284533B2 (enExample)
EP (3) EP4023749A1 (enExample)
JP (7) JP6253576B2 (enExample)
KR (7) KR102446975B1 (enExample)
CN (3) CN109652430B (enExample)
AU (5) AU2012272837B2 (enExample)
CA (4) CA3055006C (enExample)
DK (2) DK3447131T3 (enExample)
ES (1) ES2890427T3 (enExample)
MX (4) MX346625B (enExample)
WO (1) WO2012177924A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3169427B2 (ja) 1992-04-07 2001-05-28 新日本製鐵株式会社 磁気特性の優れた二方向性珪素鋼板の製造方法
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
US9284533B2 (en) 2011-06-24 2016-03-15 Flugen, Inc. Influenza virus mutants and uses therefor
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015142671A2 (en) * 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
CN118178629A (zh) 2017-02-27 2024-06-14 复尔健有限公司 针对流感的免疫原性组合物
AU2018225759B2 (en) * 2017-02-27 2024-08-15 Flugen, Inc. Influenza B virus mutants and uses therefor
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
US11214799B2 (en) * 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
MX2021014848A (es) * 2019-06-07 2022-05-03 Flugen Inc Columna vertebral del virus de la influenza.
CN110468130B (zh) * 2019-08-09 2021-08-06 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
AU2021314154A1 (en) * 2020-07-21 2023-02-09 Flugen, Inc. Vaccine using M2/BM2-deficient influenza vectors
MX2023000881A (es) 2020-07-21 2023-02-22 Flugen Inc Estructura genomica del virus de la influenza.
CN114381440B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用
CN114381439B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用
CN114438043B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗
CN114381438B (zh) * 2022-01-27 2024-02-02 浙江迪福润丝生物科技有限公司 一种流感病毒的致弱方法及流感致弱病毒株和应用
CN114410681B (zh) * 2022-01-27 2024-02-13 浙江迪福润丝生物科技有限公司 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6253576U (enExample) 1985-09-21 1987-04-02
JPH05515Y2 (enExample) 1987-12-16 1993-01-08
AU5698798A (en) 1996-12-20 1998-07-17 Procter & Gamble Company, The A dry laid structure comprising particulate material
GB9815040D0 (en) * 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
AU5533601A (en) * 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
WO2002068632A2 (en) 2001-02-23 2002-09-06 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
CA2522081C (en) * 2003-04-23 2013-01-29 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
JP5215561B2 (ja) * 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
CN1810961B (zh) 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
WO2008156778A2 (en) * 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN102089324B (zh) * 2007-11-12 2014-04-16 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
US20100061995A1 (en) * 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
AU2010243489A1 (en) * 2009-05-01 2011-12-22 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
US20110172637A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US20110172638A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172639A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
TW201303143A (zh) 2011-03-22 2013-01-16 Exxonmobil Upstream Res Co 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法
US9284533B2 (en) * 2011-06-24 2016-03-15 Flugen, Inc. Influenza virus mutants and uses therefor
JP6639334B2 (ja) 2016-06-20 2020-02-05 株式会社日立製作所 業務処理フロー生成システム、生成方法および装置
JP6120237B1 (ja) 2016-06-20 2017-04-26 仁博 平嶋 サービスシステム、アプリケーションプログラム及び決済方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Watanabe, Shinji, Tokiko Watanabe, and Yoshihiro Kawaoka., 'Influenza A virus lacking M2 protein as a live attenuated vaccine', Journal of virology, Vol. 83, 2009, pages 5947-5950. *
Watanabe, Tokiko, et al., 'Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants', Journal of virology, Vol. 82, 2008, pages 2486-2492. *

Also Published As

Publication number Publication date
JP7231666B2 (ja) 2023-03-01
KR20140037235A (ko) 2014-03-26
MX383065B (es) 2025-03-13
ES2890427T3 (es) 2022-01-19
AU2018200490B2 (en) 2020-03-19
CN109652430B (zh) 2023-05-16
EP3447131B1 (en) 2021-08-18
CA2875484C (en) 2019-11-05
CA2875484A1 (en) 2012-12-27
US11207399B2 (en) 2021-12-28
KR20180094147A (ko) 2018-08-22
DK3447131T3 (da) 2021-09-13
US9919043B2 (en) 2018-03-20
AU2012272837A1 (en) 2014-01-16
CN109652430A (zh) 2019-04-19
EP2723855B1 (en) 2018-08-08
EP2723855A4 (en) 2015-01-07
MX346625B (es) 2017-03-27
US20140127249A1 (en) 2014-05-08
WO2012177924A2 (en) 2012-12-27
US11980661B2 (en) 2024-05-14
KR102275459B1 (ko) 2021-07-09
JP2018046850A (ja) 2018-03-29
KR102446975B1 (ko) 2022-09-22
US20160228535A1 (en) 2016-08-11
EP3447131A1 (en) 2019-02-27
MX361139B (es) 2018-11-28
US11040098B2 (en) 2021-06-22
JP2023071764A (ja) 2023-05-23
US20160228534A1 (en) 2016-08-11
DK2723855T3 (en) 2018-10-01
JP6496000B2 (ja) 2019-04-03
JP2021112196A (ja) 2021-08-05
US20250090649A1 (en) 2025-03-20
US9284533B2 (en) 2016-03-15
JP2019103516A (ja) 2019-06-27
KR20180094145A (ko) 2018-08-22
NZ620242A (en) 2016-02-26
CN103781901B (zh) 2019-04-12
AU2020201760A1 (en) 2020-03-26
KR20240013286A (ko) 2024-01-30
MX2014000254A (es) 2014-10-14
AU2018200490A1 (en) 2018-02-15
EP4023749A1 (en) 2022-07-06
CA3055002A1 (en) 2012-12-27
AU2018200488A1 (en) 2018-02-08
KR102080062B1 (ko) 2020-02-21
CA3055006A1 (en) 2012-12-27
AU2020201760B2 (en) 2023-04-20
JP2014526883A (ja) 2014-10-09
JP6870017B2 (ja) 2021-05-12
AU2023204165A1 (en) 2023-08-03
KR102080061B1 (ko) 2020-02-21
WO2012177924A3 (en) 2013-09-06
JP6445662B2 (ja) 2018-12-26
KR102080914B1 (ko) 2020-02-26
CN106995802A (zh) 2017-08-01
US20190060441A1 (en) 2019-02-28
CA3055002C (en) 2021-02-09
JP6253576B2 (ja) 2017-12-27
KR20220133316A (ko) 2022-10-04
AU2012272837A2 (en) 2014-01-30
MX2021006342A (es) 2022-05-26
CN103781901A (zh) 2014-05-07
CA3103774A1 (en) 2012-12-27
KR20200021100A (ko) 2020-02-27
AU2018200488B2 (en) 2020-03-19
JP2025066111A (ja) 2025-04-22
KR20210084710A (ko) 2021-07-07
CN106995802B (zh) 2021-04-09
EP2723855A2 (en) 2014-04-30
US9919042B2 (en) 2018-03-20
US20200061182A1 (en) 2020-02-27
CA3055006C (en) 2021-02-09
JP2018046851A (ja) 2018-03-29
US20220409719A1 (en) 2022-12-29
KR102628482B1 (ko) 2024-01-23

Similar Documents

Publication Publication Date Title
US11980661B2 (en) Influenza virus mutants and uses therefor
US11980662B2 (en) Influenza virus vectors and uses therefor
HK40076573A (en) Influenza a virus mutants
HK40005266A (en) Influenza a virus mutants
HK40005266B (en) Influenza a virus mutants
NZ620242B2 (en) Influenza virus mutants and uses therefor

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 DEC 2013

FGA Letters patent sealed or granted (standard patent)